← 產業報告目錄
Onco-hematology Molecular Testing Market Size, Share & Trends Analysis Report By Blood Cancer Type, By Technology, By Blood Cancer Biomarker, By End-User, By Region, And By Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-28頁數 180報告編號 INSIGHTACE-994328e374
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 497.67 Mn as of 2022, the global Onco-hematology Molecular Testing Market is set to climb to USD 1280.06 Mn by 2031, reflecting a compound annual growth rate of 11.2% over the 2023–2031 period.
The Onco-hematology Molecular Testing sector involves The field of medicine known as oncology is dedicated to understanding the causes, diagnosis, prognosis, monitoring, and prevention of various forms of cancer. This domain has witnessed meaningful transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is driven by expanding need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and expanding investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Onco-hematology Molecular Testing Market Snapshot
Chapter 4. Global Onco-hematology Molecular Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry
Chapter 5. Market Segmentation 1: By Blood Cancer Type Estimates & Trend Analysis
5.1. By Blood Cancer Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Type:
5.2.1. Chronic Myeloid Leukemia
5.2.1.1. Polycythemia Vera
5.2.1.2. Essential Thrombocythemia
5.2.1.3. Myelofibrosis
5.2.2. Myeloproliferative Neoplasms
5.2.3. Acute Myeloid Leukemia
5.2.4. Acute Lymphoblastic Leukemia
Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Blood Cancer Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Technology:
6.2.1. qPCR
6.2.2. dPCR
6.2.3. Next-Generation Sequencing
6.2.4. Others
Chapter 7. Market Segmentation 3: By Blood Cancer Biomarker Estimates & Trend Analysis
7.1. By Blood Cancer Type & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Biomarker:
7.2.1. BCR-ABL1 Mbcr
7.2.2. JAK2
7.2.3. CALR
7.2.4. MPL
7.2.5. PML-RARA
7.2.6. NPM1
7.2.7. RUNX1-RUNX1T1
7.2.8. CBFB-MYH11
7.2.9. BCR-ABL1 mbcr
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By Blood Cancer Type & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By End User:
8.2.1. National Reference Lab / Specialty Lab
8.2.2. University Hospital / Oncology Center
8.2.3. Community Hospital / IDN (Regional/National)
Chapter 9. Onco-hematology Molecular Testing Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Type, 2023-2031
9.1.2. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.1.3. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.1.4. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By, End User 2023-2031
9.1.5. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.2.2. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.2.3. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker 2023-2031
9.2.4. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User,2023-2031
9.2.5. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.3.2. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.3.3. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.3.4. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-20
9.3.5. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.4.2. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.4.3. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.4.4. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.4.5. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, (US$ Million)
9.5.2. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.5.3. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.5.4. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.5.5. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031
9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Asusragen, Inc.
10.2.2. Bio-Rad Laboratories, Inc.
10.2.3. ICON plc
10.2.4. Illumina, Inc.
10.2.5. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
10.2.6. Invivoscribe, Inc.
10.2.7. QIAGEN N.V.
10.2.8. Thermo Fisher Scientific, Inc.
10.2.9. Cepheid
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們